413 POSTER A phase I dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies
W.P. Yong, B.C. Goh, K. Ethirajulu, P. Yeo, O. Otheris, S.M. Chao, R. Soo, W.L. Yeo, E. Seah, J. ZhuVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)72347-4
File:
PDF, 61 KB
english, 2008